研究单位：[1]Peking University People's Hospital[2]Anhui Provincial Hospital[3]The First Affiliated Hospital of Anhui Medical University[4]Peking University International Hospital[5]Xuanwu Hospital, Beijing[6]Dongguan donghua hospital[7]Sixth Affiliated Hospital, Sun Yat-sen University[8]Hebei General Hospital[9]Bethune International Peace Hospital[10]Central South University[11]The First Affiliated Hospital with Nanjing Medical University[12]Subei People's Hospital of Jiangsu Province[13]The First Affiliated Hospital of BaoTou Medical College[14]Linyi People's Hospital[15]Shandong Provincial Hospital[16]Mianyang Central Hospital[17]Tianjin Medical University General Hospital[18]The First People's Hospital of Yunnan[19]Second Affiliated Hospital, School of Medicine, Zhejiang University[20]Zhejiang Provincial People's Hospital[21]First Hospital of China Medical University[22]Xijing Hospital[23]Tianjin First Central Hospital
This study evaluate the Smart System of Disease Management（SSDM）to improve the treat-to-target(T2T) and the safety of drug in the treatment of rheumatoid(RA). All participants will be randomized in the SSDM group and the control group. The patients in the SSDM group will use the SSDM every month and the control group will receive the conventional therapy.
